Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Efficacy and Safety of Erenumab in Japanese Migraine Prevention
NCT03812224Phase 3Completed
- Sponsor
- Amgen
- Start
- Apr 2019
- Primary completion
- Mar 2020
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in migraine comparing Erenumab with Placebo (2 arms). Primary endpoint: Change From Baseline in Mean Monthly Migraine Days at 6 months. Started Apr 2019; status: completed.
02
Drugs
erenumab
03
Conditions
migraine
Beyond the preview
Go deeper on NCT03812224.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03812224.